A Study of Tislelizumab as Monotherapy in Relapsed or Refractory Classical Hodgkin Lymphoma

Beijing Cancer Hospital, Beijing

Chinese Pla General Hospital, Beijing

The First Hospital of Jilin University, Changchun

Fudan University Shanghai Cancer Center, Shanghai

Jiangsu Province Hospital, Nanjing

Institute of Hematology and Hospital of Blood Disease, Tianjin

Tianjin Medical University Cancer Institute and Hospital, Tianjin

Zhejiang Cancer Hospital, Hangzhou

Fujian Cancer Hospital, Fuzhou

Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology, Wuhan

Henan Cancer Hospital, Zhengzhou

West China Hospital, Sichuan University, Chengdu